Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment

Semaglutide is a human glucagon‐like peptide‐1 analog that has been co‐formulated with the absorption enhancer, sodium N‐(8‐[2‐hydroxybenzoyl] amino) caprylate, for oral administration. This trial (NCT02016911) investigated whether hepatic impairment affects the pharmacokinetics, safety, and tolerab...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical pharmacology 2018-10, Vol.58 (10), p.1314-1323
Hauptverfasser:	Bækdal, Tine A., Thomsen, Mette, Kupčová, Viera, Hansen, Cilie W., Anderson, Thomas W.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidiabetics GLP-1 receptor agonists Glucagon hepatic impairment Impairment Liver Oral administration Pharmacokinetics Safety semaglutide Sodium Special Populations
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!